Fulminant Hepatitis B Associated with a Specific Insertion in the Basal Core Promoter Region of Hepatitis B Virus DNA after Immunosuppressive Treatment
René Gerolami(Méditerranée Infection Foundation), Catherine Tamalet(Alphabio), Philippe Colson(Aix-Marseille Université), Daniele Botta(University of Geneva), Patrick Borentain(Hôpital de la Conception), M. Henry(Hôpital de la Timone)
Cited by 23
Related Papers
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
|The Lancet. Gastroenterology & hepatology|2019|61
Neutrophil count predicts poor outcome despite recanalization after endovascular therapy
|Neurology|2019|61
Evidence of SARS-CoV-2 re-infection with a different genotype
|Journal of Infection|2020|58
Anterior cerebral artery embolism during thrombectomy increases disability and mortality
|Journal of NeuroInterventional Surgery|2018|56